Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 6/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CHRND | Q07001 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905208 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL29615733 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL676026 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL31375263 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7836790 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3217337 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7480026 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7464746 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL905236 | 0.89 | CHRNA3 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL905201 | 0.89 | CHRNA3 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-03-05 | — | — | US | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-3713574-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | The Governors of the University of Alberta (CA) | 2020-09-30 | — | — | EP | claimed |
| CN-111629726-A | Method for combatting respiratory depression by activating neuronal heterotopic nicotinic acetylcholine receptors | 阿尔伯塔大学理事会 | 2020-09-04 | — | — | CN | claimed |
| WO-2019100155-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-05-31 | — | — | WO | claimed |
| US-20260107973-A1 | AEROSOL-MODIFYING ADDITIVE COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107972-A1 | AEROSOL GENERATING GEL MATERIAL COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-0950057-B1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LAB (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6403575-B1 | ANTI-INFLAMMATORIES | ABBOTT LABORATORIES | 2002-06-11 | — | — | US | disclosed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6133253-A | NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0950057-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | Abbott Laboratories (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, CHRM1 | CHRNB2 504/4885CHRNA4 195/4885CHRNA3 200/4885 |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | ALK, EXOSC4, EXOSC9 | CHRNB2 755/4885CHRNA4 472/4885CHRNA3 455/4885 |
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EXOSC4, CHRM3 | CHRNB2 319/4885CHRNA4 292/4885CHRNA3 244/4885 |
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | CHRM3, CHRM1, ADRA1D | CHRNB2 240/4885CHRNA4 119/4885CHRNA3 126/4885 |
| US-20260107973-A1 | AEROSOL-MODIFYING ADDITIVE COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | CHRM3, CHRM1, CHRM2 | CHRNB2 256/4885CHRNA4 165/4885CHRNA3 116/4885 |
| US-20260107972-A1 | AEROSOL GENERATING GEL MATERIAL COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | ACTN1, ARPC3, ARPC4 | CHRNB2 411/4885CHRNA4 312/4885CHRNA3 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.